Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome

Brian E. Lacy, John M. Levenick, Michael D. Crowell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalGastroenterology and Hepatology
Volume8
Issue number10
StatePublished - Oct 2012

Fingerprint

Irritable Bowel Syndrome
Constipation
Diet Therapy
Therapeutics
Gastrointestinal Diseases
Pharmaceutical Preparations
Economics
Quality of Life
linaclotide
Exercise
Delivery of Health Care
Population

Keywords

  • Abdominal pain
  • Bloating
  • Constipation
  • Guanylyl cyclase
  • Irritable bowel syndrome
  • Linaclotide

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Linaclotide : A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome. / Lacy, Brian E.; Levenick, John M.; Crowell, Michael D.

In: Gastroenterology and Hepatology, Vol. 8, No. 10, 10.2012, p. 653-660.

Research output: Contribution to journalArticle

Lacy, Brian E. ; Levenick, John M. ; Crowell, Michael D. / Linaclotide : A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome. In: Gastroenterology and Hepatology. 2012 ; Vol. 8, No. 10. pp. 653-660.
@article{81d437049f3f4718b30ebd4d6525fce1,
title = "Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome",
abstract = "Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12{\%} of the US population meet the diagnostic criteria for IBS, and 15{\%} meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.",
keywords = "Abdominal pain, Bloating, Constipation, Guanylyl cyclase, Irritable bowel syndrome, Linaclotide",
author = "Lacy, {Brian E.} and Levenick, {John M.} and Crowell, {Michael D.}",
year = "2012",
month = "10",
language = "English (US)",
volume = "8",
pages = "653--660",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "10",

}

TY - JOUR

T1 - Linaclotide

T2 - A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome

AU - Lacy, Brian E.

AU - Levenick, John M.

AU - Crowell, Michael D.

PY - 2012/10

Y1 - 2012/10

N2 - Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

AB - Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

KW - Abdominal pain

KW - Bloating

KW - Constipation

KW - Guanylyl cyclase

KW - Irritable bowel syndrome

KW - Linaclotide

UR - http://www.scopus.com/inward/record.url?scp=84868030495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868030495&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84868030495

VL - 8

SP - 653

EP - 660

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 10

ER -